COMBINED THERAPY FOR HYPERTENSION AND CEREBRAL BLOOD FLOW INDICATORS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The impact of 6-month combined antihypertensive therapy with a calcium antagonist and an angiotensin-converting enzyme inhibitor (amlodipine with ramipril) on cerebral blood flow indicators in hypertensive patients working in the Far North has been evaluated.

Full Text

Restricted Access

About the authors

I. Zapesochnaya

Nizhnevartovsk Town Polyclinic

Email: zapesochnaya.irina@bk.ru

A. Avtandilov

Russian Medical Academy of Postgraduate Education

A. Timofeeva

Russian Medical Academy of Postgraduate Education

M. Chubarov

Russian Medical Academy of Postgraduate Education

References

  1. Erbel R., Lehmann N., Möhlenkamp S. et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the heinz nixdorf recall study // Hypertension. - 2012; 59 (1): 44-53.
  2. Redon J., Olsen M., Cooper R. et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure // Eur. Heart J. - 2011; 32: 1424-31.
  3. Rothwell P., Howard S., Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet. - 2010; 375: 895-905.
  4. Сорокин Е.В., Карпов Ю.А. Комбинированная антигипертензивная терапия - ключ к повышению эффективности сердечно-сосудистой профилактики // Рус. мед. журн. - 2012; 25: 91-100.
  5. Breekveldt-Postma N., Penning-van Beest F., Siiskonen S. et al. Effect of persistent use of antihypertensives on blood pressure goal attainment // Curr. Med. Res. Opin. - 2008; 24: 1025-31.
  6. Kettani F., Dragomir A., Cote R. et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention // Stroke. - 2009; 40: 213-20.
  7. Шальнова С.А., Кукушкин С., Маношкина Е. и др. Артериальная гипертензия и приверженность к терапии // Врач. - 2009; 12: 39-42.
  8. Jamerson K., Weber M., Bakris G. et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients // N. Engl. J. Med. - 2008; 359: 2417-28.
  9. Dahlof B., Sever P., Poulter N. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. - 2005; 366: 895906.
  10. Bertrand M., Ferrari R., Remme W. et al. On behalf of the EUROPA Investigators. Synergistic effect of perindopril and calcium channel blockers in revention of cardiac events and death in coronary artery disease patients: analysis from the EUROPA study // Am. Heart J. - 2010; 159: 795-802.
  11. Law M., Morris J., Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. - 2009; 338: b1665.
  12. Подзолков В.И., Тарзиманова А.И. Новая фиксированная комбинация рамиприла и амлодипина в лечении артериальной гипертензии // Рац. фармакот. в кардиол. - 2015; 11 (3): 327-32.
  13. Чазова И.Е., Мартынюк Т.В., Ратова Л.Г. В фокусе внимания - ингибиторы ангиотензинпревращающего фермента: рамиприл при артериальной гипертонии // Системные гипертензии. - 2011; 3: 5-10.
  14. Рабочая группа по лечению артериальной гипертонии Европейского общества гипертонии (European Society of Hypertension, ESH) и Европейского общества кардиологов (European Society of Cardiology, ESC). Рекомендации по лечению артериальной гипертонии // Рос. кардиол. журн. - 2014; 1 (105): 7-94.
  15. Nambi V., Chambless L., Folsom A. et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study // J. Am. Coll. Cardiol. - 2010; 55: 1600-7.
  16. Mallareddy M., Parikh C., Peixoto A. Effect of angiotensinconverting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis // J. Clin. Hypertens (Greenwich). - 2006; 8 (6): 398-403.
  17. Zanchetti A., Bond M., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine study on Atherosclerosis (ELsA), a randomized, double-blind, long-term trial // Circulation. - 2002; 106: 2422-7.
  18. Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии // Consilium Меdicum. -2006; 8 (11): 113-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Russkiy Vrach Publishing House